Denis Corin, President and CEO of Q BioMed Inc. (OTCQB: QBIO) Talks to
Daniel Levine of the Bio Report
Pharma Bro, Price Controls, and the Quest to Balance Innovation with
Affordability; Perspective on the fallout from Shkreli
March 2, 2016 - Investorideas.com a global digital
media source covering leading sectors including biotech stocks profiles the
following biotech interview. Denis Corin, President and CEO of Q BioMed Inc. (OTCQB: QBIO) talks with Daniel
Levine of the Bio Report about some recent controversial topics in the
sector.
The Bio Report Podcast Overview:
The embattled pharma executive Martin Shkreli, whether intentional or
not, has ignited a long smoldering public policy discussion about the pricing
of pharmaceuticals. As there are growing calls for steps to restrain drug
prices, there are also industry concerns about the effect such actions would
have on the ability to attract investment and pursue the development of
high-risk, innovative therapies. We spoke to Denis Corin, CEO of Q BioMed, an
acceleration and development company, for a perspective on the fallout from
Shkreli, how to balance innovation with affordability, and whether he expects
any lasting impacts on small drug developers.
Podcast with Danny Levin: https://soundcloud.com/levine-media-group/pharma-bro-price-controls-and-the-quest-to-balance-innovation-with-affordability
It can also be watched at
The Bio Report podcast, hosted by veteran
journalist Daniel Levine, focuses on the intersection of biotechnology with
business, science, and policy.
Read this release in full at http://www.investorideas.com/CO/QBIO/news/2016/03021.asp
About Q BioMed Inc. (OTCQB: QBIO)
Q BioMed Inc. ("Q") is a biomedical
acceleration and development company. We are focused on acquiring companies and
biomedical assets. Q is dedicated to providing these target companies and
assets, strategic resources, developmental support, and expansion capital to
ensure they meet their developmental potential enabling them to provide
products to patients in need.
About Investorideas.com - Big Ideas for
Global Investors
InvestorIdeas.com -
digital media global news source, PR and social media in leading sectors
including Biotech.
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: QBIO has retained investorideas.com for PR, media, news publication
and social media effective February 5th for three months: two thousand five
hundred per month
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
Contact Investorideas.com
800 665 0411
No comments:
Post a Comment